Alkermes, Inc.
Clinical trials sponsored by Alkermes, Inc., explained in plain language.
A biopharmaceutical company developing treatments for central nervous system diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New combo pill aims to curb weight gain in teens on antipsychotics Results expected Sep 2026 (estimated)
- New pill aims to fight excessive daytime sleepiness Results expected Nov 2026 (estimated) May already have reported ↗
- New narcolepsy pill aims to banish daytime drowsiness Results expected May 2027 (estimated)
- New pill aims to fight daytime sleepiness and sudden muscle collapse Results expected May 2027 (estimated)
- New pill aims to keep narcolepsy patients awake and steady Results expected Jun 2027 (estimated)
-
New combo pill aims to curb weight gain in teens on antipsychotics
Disease control Recruiting nowThis study tests whether a combination drug called OLZ/SAM (olanzapine plus samidorphan) causes less weight gain than olanzapine alone in teenagers with schizophrenia or bipolar I disorder. About 220 teens aged 10-17 will take either the combo or olanzapine for 52 weeks. The main…
Phase 3 • Sponsor: Alkermes, Inc. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Could a new pill tame adult ADHD symptoms?
Disease control Recruiting nowThis phase 2 trial is testing whether an experimental tablet called ALKS 7290 can reduce ADHD symptoms in adults. About 312 adults with ADHD will take either the drug or a placebo daily for 4 weeks. Researchers will measure changes in symptom scores and watch for side effects to …
Phase 2 • Sponsor: Alkermes, Inc. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a Two-Drug combo help teens with severe mental illness?
Disease control Expanded accessThis expanded access program offers continued treatment with OLZ/SAM, a combination of olanzapine and samidorphan, to adolescents with schizophrenia or bipolar I disorder who have already completed a year-long study of the drug. The goal is to provide ongoing access to the medica…
Sponsor: Alkermes, Inc. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New narcolepsy pill aims to banish daytime drowsiness
Symptom relief Recruiting nowThis study tests a new tablet called ALKS 2680 to see if it can reduce daytime sleepiness in adults with narcolepsy type 2. About 176 participants will receive either the study drug or a placebo for 12 weeks. The main goal is to measure how well they can stay awake using a standa…
Phase 3 • Sponsor: Alkermes, Inc. • Aim: Symptom relief
Last updated Sep 05, 2026 00:00 UTC
-
New pill aims to fight daytime sleepiness and sudden muscle collapse
Symptom relief Recruiting nowThis phase 3 trial tests whether a daily tablet called ALKS 2680 can reduce daytime sleepiness and cataplexy (sudden muscle weakness) in 150 adults with narcolepsy type 1. Participants will take the drug or a placebo for 12 weeks, and researchers will measure changes in sleep tes…
Phase 3 • Sponsor: Alkermes, Inc. • Aim: Symptom relief
Last updated Sep 05, 2026 00:00 UTC
-
New pill aims to keep narcolepsy patients awake and steady
Symptom relief Recruiting nowThis phase 3 trial tests whether a daily tablet called ALKS 2680 can reduce severe daytime sleepiness and sudden muscle weakness (cataplexy) in adults with narcolepsy type 1. About 150 participants will receive either the drug or a placebo for 12 weeks. The study measures improve…
Phase 3 • Sponsor: Alkermes, Inc. • Aim: Symptom relief
Last updated Sep 05, 2026 00:00 UTC
-
New pill shows promise for keeping people with narcolepsy awake longer
Symptom relief Recruiting nowThis study is testing the long-term safety and how well ALKS 2680 works over time in people with narcolepsy type 1, type 2, or idiopathic hypersomnia. Participants take a once-daily tablet at different doses. The goal is to see if the drug remains safe and effective for staying a…
Phase 2/3 • Sponsor: Alkermes, Inc. • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
New pill aims to fight excessive daytime sleepiness
Symptom relief Recruiting nowThis study tests a new drug called ALKS 2680 to see if it can safely reduce daytime sleepiness in people with idiopathic hypersomnia, a condition causing excessive sleepiness without clear cause. About 126 participants will receive either the drug or a placebo daily for 8 weeks. …
Phase 2 • Sponsor: Alkermes, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 14:03 UTC